Celebrating Pharmacy Innovation at the House of Commons

Alliance Healthcare celebrated the very best in pharmacy at the House of Lords as sponsors of the Innovation Awards at the Independent Pharmacy Awards.

Raj Nutan, Healthcare Strategy and Services Director, Alliance Healthcare and Sam Unsworth, Head of Communications, Alliance Healthcare had the honour to represent Alliance Healthcare at the prestigious setting, where Sam presented the award and said: “Innovation is essential to deliver the best service to patients. That’s why Alliance Healthcare is delighted to sponsor the Innovation Award at the Independent Pharmacy Awards.”

Deborah Evans, Remedi Health, Hampshire was our winner, who wowed the judges with her ability to not only lead but think outside the box.

Deborah has worked in pharmacy for over 35 years and runs a GpHC-registered private pharmacy which only opened last year. She has pulled together a brilliant team of 12 who have rolled out a range of private services for their patients – and in deciding not to provide NHS services, she has made a real success of her business in very tough times.

Her business model reverses the traditional community pharmacy approach. Instead of her predominately prescription and medicines business that offers services, hers is predominately a clinical service business of which medicines and prescriptions are part of the solution for the clients. The judges described Deborah as “an inspiration.”

Find out more about the awards here.

Company Led Recall - Endwarts freeze 7.5g

Viatris have informed that product Endwarts Freeze^® has been manufactured with 5 tips instead of the stipulated 7 as indicated on the packaging and leaflet.

MHRA drug alert link: N/A   

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

For more information please contact VIATRIS UK HEALTHCARE

Gary Marshall Gary.marshall@viatris.com 07817 486960

Class 4 Medicines Defect Information: Flamingo Pharma UK Ltd, Ibuprofen 400mg Tablets, Paracetamol 500mg Tablets (Caplets)

Flamingo Pharma UK Ltd has identified an error relating to the ink printing of the batch number and expiry date on the carton for three batches of Ibuprofen 400mg Tablets. This notification includes all potentially impacted products/batches.

MHRA drug alert date:  12th October 2022

MHRA drug alert link: 

https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-flamingo-pharma-uk-ltd-ibuprofen-400mg-tablets-paracetamol-500mg-tablets-caplets-el-22-a-slash-43?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=ffbd7a57-60fc-4de6-afd0-d1d3fb960b3e&utm_content=immediately#download-document

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

Further Information

For medical information and stock control queries please contact:

Flamingo Pharma

For medical information safety@flamingopharma.co.uk or general product enquiry sales@flamingopharma.co.uk +44 (0) 7733522465

Or

Mawdsley Brooks & Co Ltd

Overlabellingcustomerservices@mawdsleys.co.uk 01302 553064

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

CLASS 2 RECALL - AMIODARONE HYDROCHLORIDE 50MG/ML SOLUTION FOR INJECTION/INFUSION

hameln pharma ltd is initiating a recall of batch 210505 of Amiodarone Hydrochloride 50 mg/ml Concentrate for Solution for Injection/Infusion as a precautionary measure. This is due to an increased presence of visible crystalline particles within the solution, identified during ongoing re-inspection of retained samples.

MHRA drug alert date: 11 October 2022

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-hameln-pharma-ltd-amiodarone-hydrochloride-50-mg-slash-ml-concentrate-for-solution-for-injection-slash-infusion-el-22-a-slash-42?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=8736ec08-585b-4e2f-9985-026dc8594eef&utm_content=immediately

Alliance do not stock the above products so we will not be accepting Customer returns on this recall.

For more information or supply queries, please contact or email hameln pharma ltd customer services on +44 (0)1452 621 661 or customer.services@hameln-pharma.co.uk

For medical information queries, please contact or email hameln pharma ltd Medicines Information on +44 (0)1452 621 661 or drug.safety@hameln-pharma.co.uk

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

CLASS 2 RECALL - STEMETIL 5MG/5ML SYRUP

Sanofi is recalling all batches of the above product as a precautionary measure due to the identification of N-nitrosomethylphenylamine (NMPA) above the acceptable limit. Nitrosamines may increase the risk of cancer if people are exposed to them above acceptable levels and over long periods of time.

MHRA drug alert date: 10 October 2022

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-aventis-pharma-limited-t-slash-a-sanofi-stemetil-5mg-slash-5ml-syrup-el-22-a-slash-41?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=8744b402-2664-40d4-a81b-0fbedeefc431&utm_content=immediately

Alliance do not stock the above products so we will not be accepting Customer returns on this recall.

For stock control enquiries please contact:

GB-CustomerServices@sanofi.com

Phone number: 0800 854 430

For more information or medical information please contact:

uk-medicalinformation@sanofi.com

Phone number: 0800 035 25 25.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Janssen Neuroscience RWA

We are pleased to announce that, as of 01 November 2022, Alliance Healthcare will become the only wholesaler to supply selected products from Janssen’s neuroscience product portfolio to all pharmacies, hospitals, and dispensing doctors in Great Britain. Supply to Northern Ireland is not included in this agreement.

A full list of the selected products is available here.

Some service disruption - 29 September 2022

Due to a network issue overnight which has since been fully resolved, there may be some disruption to service across our network (except Northern Ireland). Impacted customers are being contacted. We are sorry for any inconvenience caused.

Please contact Customer Service with any emergency requirements.

World Pharmacist Day 2022

World Pharmacist Day: Celebrating the changing face of modern pharmacy to create healthier futures

On Sunday 25 September we celebrated the International Pharmaceutical Federation’s (FIP) World Pharmacist Day 2022. As part of those celebrations, 27 pharmacists from across the globe and the AmerisourceBergen family, contributed to a digital book of celebration, which aims to highlight the changing role of pharmacists and how they can create healthier futures. 

The book, which was developed as part celebrations for the FIP World Pharmacist Day, which this year is focusing on “pharmacy united in action for a healthier world” - also highlights how pharmacists have a key role in creating a healthier world and keeping our communities fit and healthy. 

Read more...

CLASS 2 RECALL - SANDIMMUN ORAL SOLUTION

Class 2 Recall -  Sandimmun Oral Solution

Novartis Pharmaceuticals UK are recalling the above batch due to the presence of crystals in the solution. The crystals have been identified as the active substance (ciclosporin). The presence of crystals has been observed in some finished product packs marketed in other countries that share the same master batch as the UK batch above. Therefore, this UK batch is recalled as a precautionary measure. Novartis Pharmaceuticals UK have confirmed no other batches of the product are impacted.

MHRA drug alert date: 20 September 2022

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-novartis-pharmaceuticals-uk-sandimmun-oral-solution-el-22-a-slash-40?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=8bfa30ef-b0bd-4cf8-8ca4-e989982960bf&utm_content=immediately

Alliance do not stock the above products so we will not be accepting Customer returns on this recall.

Further Information For more information, medical or supply enquiries. 

Please contact 01276 698370, or email medinfo.uk@novartis.com

Class 4 Medicines Defect Information

Rosemont Pharmaceuticals Ltd. has made the MHRA aware that the expiry dates stamped on the base of the bottle are incorrect for 2 batches of Atorvastatin 4mg/ml Oral Suspension and 2 batches of Sildenafil 10mg/ml Oral Suspension.

MHRA drug alert date:  14 September 2022

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-rosemont-pharmaceuticals-ltd-atorvastatin-4mg-slash-ml-oral-suspension-and-sildenafil-10mg-slash-ml-oral-suspension-el-22-a-slash-39

This is a caution in use only we are not accepting stock returns - if any defective stock is found it should be returned directly to the manufacturer.

Further Information

For more information, medical or supply enquiries, please contact: pharmacovigilance@rosemontpharma.com

Recipients of this Medicines Notification should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.